Novartis India Limited (NOVARTIND.BO)
INR 998.85
(-1.78%)
INR 998.85
(-1.78%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.35 Billion INR | -9.22% |
| 2022 | 3.69 Billion INR | -4.76% |
| 2021 | 3.87 Billion INR | 6.01% |
| 2020 | 3.65 Billion INR | -11.12% |
| 2019 | 4.11 Billion INR | -8.66% |
| 2018 | 4.5 Billion INR | -12.93% |
| 2017 | 5.17 Billion INR | -15.15% |
| 2016 | 6.09 Billion INR | -11.63% |
| 2015 | 6.89 Billion INR | -21.02% |
| 2014 | 8.73 Billion INR | 1.29% |
| 2013 | 8.62 Billion INR | -4.55% |
| 2012 | 9.03 Billion INR | 7.0% |
| 2011 | 8.44 Billion INR | 12.39% |
| 2010 | 7.51 Billion INR | 20.37% |
| 2009 | 6.24 Billion INR | 4.11% |
| 2008 | 5.99 Billion INR | 8.32% |
| 2007 | 5.53 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 922.9 Million INR | 13.7% |
| 2024 Q2 | 871 Million INR | -5.62% |
| 2023 Q4 | 811.7 Million INR | -3.99% |
| 2023 FY | 3.35 Billion INR | -9.22% |
| 2023 Q2 | 787.6 Million INR | -13.07% |
| 2023 Q3 | 845.4 Million INR | 7.34% |
| 2023 Q1 | 906 Million INR | 36.24% |
| 2022 Q2 | 1.01 Billion INR | -16.04% |
| 2022 Q3 | 801.7 Million INR | -21.03% |
| 2022 FY | 3.69 Billion INR | -4.76% |
| 2022 Q4 | 665 Million INR | -17.05% |
| 2022 Q1 | 1.2 Billion INR | 40.57% |
| 2021 Q4 | 860.2 Million INR | -13.08% |
| 2021 FY | 3.87 Billion INR | 6.01% |
| 2021 Q1 | 981.1 Million INR | 17.43% |
| 2021 Q2 | 1.04 Billion INR | 6.49% |
| 2021 Q3 | 989.6 Million INR | -5.28% |
| 2020 FY | 3.65 Billion INR | -11.12% |
| 2020 Q3 | 937.7 Million INR | -2.15% |
| 2020 Q1 | 924.6 Million INR | 38.41% |
| 2020 Q4 | 835.5 Million INR | -10.9% |
| 2020 Q2 | 958.3 Million INR | 3.64% |
| 2019 Q1 | 1.09 Billion INR | 56.07% |
| 2019 Q4 | 668 Million INR | -43.13% |
| 2019 FY | 4.11 Billion INR | -8.66% |
| 2019 Q2 | 1.17 Billion INR | 7.75% |
| 2019 Q3 | 1.17 Billion INR | -0.27% |
| 2018 FY | 4.5 Billion INR | -12.93% |
| 2018 Q4 | 700.4 Million INR | -48.36% |
| 2018 Q3 | 1.35 Billion INR | 27.25% |
| 2018 Q2 | 1.06 Billion INR | -22.82% |
| 2018 Q1 | 1.38 Billion INR | 10.2% |
| 2017 Q1 | 1.14 Billion INR | -21.09% |
| 2017 FY | 5.17 Billion INR | -15.15% |
| 2017 Q3 | 1.56 Billion INR | -6.89% |
| 2017 Q2 | 1.67 Billion INR | 46.02% |
| 2017 Q4 | 1.25 Billion INR | -19.72% |
| 2016 Q1 | 1.71 Billion INR | 2.42% |
| 2016 Q2 | 1.75 Billion INR | 2.19% |
| 2016 FY | 6.09 Billion INR | -11.63% |
| 2016 Q4 | 1.45 Billion INR | -11.49% |
| 2016 Q3 | 1.64 Billion INR | -6.1% |
| 2015 FY | 6.89 Billion INR | -21.02% |
| 2015 Q4 | 1.67 Billion INR | -13.0% |
| 2015 Q3 | 1.92 Billion INR | -14.18% |
| 2015 Q2 | 2.24 Billion INR | 0.51% |
| 2015 Q1 | 2.22 Billion INR | 7.34% |
| 2014 FY | 8.73 Billion INR | 1.29% |
| 2014 Q1 | 2.08 Billion INR | 4.08% |
| 2014 Q2 | 2.34 Billion INR | 12.47% |
| 2014 Q3 | 2.22 Billion INR | -5.36% |
| 2014 Q4 | 2.07 Billion INR | -6.55% |
| 2013 Q4 | 2 Billion INR | -10.27% |
| 2013 FY | 8.62 Billion INR | -4.55% |
| 2013 Q3 | 2.23 Billion INR | 4.49% |
| 2013 Q2 | 2.13 Billion INR | -4.11% |
| 2013 Q1 | 2.23 Billion INR | 4.82% |
| 2012 Q4 | 2.12 Billion INR | -8.96% |
| 2012 FY | 9.03 Billion INR | 7.0% |
| 2012 Q1 | 2.19 Billion INR | 8.22% |
| 2012 Q2 | 2.37 Billion INR | 8.15% |
| 2012 Q3 | 2.33 Billion INR | -1.53% |
| 2011 FY | 8.44 Billion INR | 12.39% |
| 2011 Q2 | 2.18 Billion INR | 0.0% |
| 2011 Q3 | 2.22 Billion INR | 1.53% |
| 2011 Q4 | 2.02 Billion INR | -8.75% |
| 2010 FY | 7.51 Billion INR | 20.37% |
| 2009 FY | 6.24 Billion INR | 4.11% |
| 2008 FY | 5.99 Billion INR | 8.32% |
| 2007 FY | 5.53 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Ajanta Pharma Limited | 42.08 Billion INR | 92.039% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 20.454% |
| Sigachi Industries Limited | 3.98 Billion INR | 16.013% |
| Bal Pharma Limited | 3.39 Billion INR | 1.223% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 73.841% |
| Medico Remedies Limited | 1.44 Billion INR | -131.209% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -221.148% |
| Venus Remedies Limited | 5.91 Billion INR | 43.348% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -343.535% |
| Alpa Laboratories Limited | 1.08 Billion INR | -208.142% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 80.104% |
| Shilpa Medicare Limited | 11.51 Billion INR | 70.904% |
| Aarti Drugs Limited | 25.28 Billion INR | 86.749% |
| Lupin Limited | 200.1 Billion INR | 98.326% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 98.833% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 98.238% |
| Windlas Biotech Limited | 6.3 Billion INR | 46.895% |
| Suven Life Sciences Limited | 116.92 Million INR | -2765.585% |
| Eris Lifesciences Limited | 20.09 Billion INR | 83.323% |
| Valiant Laboratories Limited | 1.82 Billion INR | -84.047% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 90.383% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 72.943% |
| Ipca Laboratories Limited | 76.22 Billion INR | 95.604% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 56.498% |
| Achyut Healthcare Limited | 61.36 Million INR | -5359.923% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.309% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 29.223% |
| RPG Life Sciences Limited | 5.82 Billion INR | 42.433% |
| Mankind Pharma Limited | 103.34 Billion INR | 96.758% |
| Laurus Labs Limited | 50.01 Billion INR | 93.301% |
| Piramal Pharma Limited | 81.71 Billion INR | 95.899% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -29.249% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 96.841% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 94.518% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 97.164% |
| Unichem Laboratories Limited | 16.57 Billion INR | 79.784% |
| Sequent Scientific Limited | 13.69 Billion INR | 75.538% |
| Wanbury Limited | 5.75 Billion INR | 41.793% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 68.13% |
| Wockhardt Limited | 27.89 Billion INR | 87.986% |
| Themis Medicare Limited | 3.81 Billion INR | 12.23% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -60.549% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 95.001% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 85.325% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 98.8% |
| Divi's Laboratories Limited | 78.45 Billion INR | 95.729% |
| NATCO Pharma Limited | 40.02 Billion INR | 91.627% |
| Gufic Biosciences Limited | 8.06 Billion INR | 58.462% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 84.187% |
| Ind-Swift Limited | 5.02 Billion INR | 33.315% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 70.895% |
| FDC Limited | 19.42 Billion INR | 82.755% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -564.538% |
| Granules India Limited | 45.06 Billion INR | 92.565% |
| Medicamen Biotech Limited | 1.79 Billion INR | -86.87% |
| Alkem Laboratories Limited | 126.67 Billion INR | 97.355% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 74.136% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -736.936% |
| Brooks Laboratories Limited | 794.86 Million INR | -321.545% |
| Megasoft Limited | 373.95 Million INR | -796.022% |
| ZIM Laboratories Limited | 3.67 Billion INR | 8.806% |
| Strides Pharma Science Limited | 40.51 Billion INR | 91.729% |
| Neuland Laboratories Limited | 15.58 Billion INR | 78.502% |
| Morepen Laboratories Limited | 17.01 Billion INR | 80.312% |
| Hikal Limited | 17.84 Billion INR | 81.224% |
| Indoco Remedies Limited | 17.89 Billion INR | 81.275% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 81.544% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -117.053% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | 9.095% |
| Hester Biosciences Limited | 3.04 Billion INR | -10.023% |